In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.
Where this comes from
- Record sourced from PubMed, PMID 32539520.
- Also identified by DOI 10.7326/ACPJ202006160-063.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cao B, Wang Y, Wen D, et al. <b>A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19.</b> N Engl J Med. 2020;382:1787-99. 32187464.
Medical subject headings
- Pneumonia, Viral
- Ritonavir